Amgen's Pipeline Under Scrutiny as Market Waits for Next Move

Amgen's management raised its full-year revenue forecast by 2.6% on August 4, 2026, a significant boost for the company.

This increase reflects real growth across Amgen's portfolio, where six key drivers collectively grew at a 26% year-over-year clip.

The market is not ignoring this good news, but it's looking beyond it. Investors have already rewarded Amgen stock with a 48% climb over the past year and trading near its 52-week peak.

The question on everyone's mind now is whether the company's pipeline, particularly the experimental weight-loss treatment MariTide, can justify the next leg up in the stock price.